Genzyme/Third Wave
This article was originally published in The Gray Sheet
Executive Summary
Firms form preferred marketing relationship for Third Wave's Invader UGT1A1 molecular assay, which assesses the potential of adverse reactions to the chemotherapy drug Camptosar (Pfizer) for colorectal cancer. The test was 510(k)-cleared in August (1"The Gray Sheet" Aug. 29, 2005, p. 26). Genzyme announced exclusive diagnostic rights to the UCLA Jonsson Cancer Center's discovery of gene mutations associated with drug resistance to Novartis' Gleevec, used to treat chronic myeloid leukemia, Oct. 6...